Cerba HealthCare (Cerba HealthCare), together with Partners Group, a global private markets firm, and the Public Sector Pension Investment Board (PSP Investments), one of Canada’s largest pension investment managers, has entered into exclusive discussions with the EQT IX fund (EQT Private Equity) to enable the Company to continue its long-term innovation services strategy and enhance services for patients and the medical community.
Cerba HealthCare, headquartered in France and firmly established in Europe and Africa through its historical routine and specialty biology expertise, also operates globally through its clinical trials business unit for the validation of new compounds and vaccines. The Company has experienced significant transformation under Partners Group’s ownership (on behalf of its clients), enhancing its operations in new markets and expanding its international footprint. It now stands as a unique company in the diagnosis market, covering the needs for diagnostic tools and expertise for patients, physicians, hospitals and the pharmaceutical industry.
With this new partnership, Cerba HealthCare reinforces its capital structure around its pool of existing long-time shareholders – more than 400 biologists and managers – together with its Canadian partner PSP Investments to sustain the Company’s development strategy and current transformation. The transaction represents an exit for Partners Group after its initial investment in 2017.
Catherine Courboillet, CEO, Cerba HealthCare, states: “Over the past four years, Partners Group has shown a comprehensive operational understanding of our market and unwavering support in sustaining Cerba HealthCare’s growth strategy. In order to continue to fulfill the Company’s long-term development, we are excited to welcome a partner that shares the same vision and values, as well as a strong understanding of the importance of cutting-edge, personalized services.”
Kim Nguyen, Partner, Private Equity Europe, Partners Group, adds: “Cerba HealthCare operates in an important sector and we are proud to have successfully contributed to the sustainable growth strategy of the Company over the last four years. In line with Partners Group’s focus on positive stakeholder impact and entrepreneurial governance, Cerba HealthCare has not wavered in its commitment to responding to the COVID-19 crisis. During our holding period, the Company has transformed into a market leader, penetrating new international markets, including in Africa and Italy, further consolidating its expertise in clinical trials and securing leadership in the veterinary biology sector. We are convinced Cerba HealthCare is poised for lasting success and that, after our strong and collaborative partnership, it is the right time and opportunity for all stakeholders that the Company move into its next phase of growth.”
The completion of the deal is subject to the legislative information process involving the Company’s works council and regulatory approvals.
